DEA Buries Exempt Status for Dead Butalbital Drugs
Published Date: 10/9/2026
Rule
Summary
The DEA is removing the special exemption for certain inactive butalbital prescription products that are no longer made or sold. Starting November 9, 2026, these products won’t be treated as exempt under drug laws anymore, but active products stay the same. This change mainly affects drug companies and pharmacies handling these old products, with no new costs for active medicines.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Exemption Revoked for Inactive Butalbital NDCs
DEA is removing exemption status for certain butalbital prescription products whose National Drug Codes (NDCs) are inactive. DEA determined that 160 of the NDCs for butalbital products on its exempt list are no longer active, and those inactive NDCs will be removed from the Table of Exempted Prescription Products effective November 9, 2026.
Active Butalbital Products Remain Unchanged
If a butalbital product still has an active NDC and is currently marketed, nothing changes for that product—the exemption status remains in place and active products are unaffected. The rule explicitly states it does not impact exempted prescription products with active NDC numbers and will not create new costs for active medicines.
Removed Products Can Still Be Sold If Compliant
Although certain inactive butalbital NDCs are being removed from the exempt list, any product that is no longer exempted may still be manufactured and sold so long as the company and product conform to all DEA regulations and the Controlled Substances Act. DEA noted the removals reflect market status and confirmed with FDA that the listed NDCs are no longer marketed.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
2026-20748, Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction
The DEA fixed a small mistake in their August 2026 rule that put O-desmethyltramadol and all its related forms into Schedule I, meaning it's now officially a highly controlled substance. This correction makes sure every version of the drug is covered, starting retroactively from August 12, 2026, through August 12, 2028. Anyone handling this drug should know it’s tightly regulated now, with no changes to fees but serious legal controls in place.
Previous / Next Documents
Previous: 2026-20748, Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction
The DEA fixed a small mistake in their August 2026 rule that put O-desmethyltramadol and all its related forms into Schedule I, meaning it's now officially a highly controlled substance. This correction makes sure every version of the drug is covered, starting retroactively from August 12, 2026, through August 12, 2028. Anyone handling this drug should know it’s tightly regulated now, with no changes to fees but serious legal controls in place.
Next: 2026-20792, Raisins Produced From Grapes Grown in California; Order Amending Marketing Order No. 989
California raisin producers just voted to shake things up! The USDA is cutting the Raisin Committee from 47 to 21 members, changing how reps are chosen, and tweaking rules about raisin quality and marketing. These changes kick in on November 9, 2026, aiming to make raisin handling smoother and more modern without extra costs.